Expanding Accessibility to High-Resolution MS Data with the First SmartMS-Enabled LC-MS Biopharma System

Waters Corporation has introduced the BioAccord™ System, a purposefully designed liquid chromatography-mass spectrometry (LC-MS) solution that will expand access to high-resolution time-of-flight mass spectrometry capabilities to more scientists. The BioAccord System promises to move routine monitoring out of centralized MS labs and into the hands of more scientists by enabling more effective analysis of biotherapeutic protein attributes across development and within quality control organizations.

"The pace of innovation in the biopharmaceutical industry is accelerating, and with it, the monitoring requirements for biotherapeutics are growing exponentially," said Chris O'Connell, Chairman and CEO, Waters Corporation. "The inherent complexity of these therapies, combined with rising regulatory standards, are driving more intensive and widespread testing requirements. Waters designed the BioAccord System as a fit-for-purpose LC-MS biopharmaceutical solution to deliver rich mass spectrometry data for improved productivity and effective decision-making."

The BioAccord System pairs ACQUITY™ UPLC™ I-Class Plus with the newly-developed ACQUITY RDa™ Detector featuring SmartMS™. This system offers new levels of user experience, with automated setup and self-diagnosis delivered through an intuitive user interface, all within a surprisingly small footprint. Powered by UNIFI™, Waters’ compliance-ready LC-MS informatics platform, the BioAccord System has been optimized for intact protein, released glycan, and peptide monitoring applications, and streamlined by the use of Waters' application-specific chemistries and consumables kits.

The BioAccord will be showcased at the American Society for Mass Spectrometry’s (ASMS) Annual Meeting in Atlanta, Georgia, USA, from June 2-6, 2019.

Learn more about Waters' events at ASMS 2019, and register, here.